Medicine-induced Cardiac Hemodialysis on COVID-19

February 1, 2023 updated by: Yang I. Pachankis

Cardiac Transfer of SARS-CoV-2 Spike Protein Circulation Techniques - Medicine Induced Hemodialysis on "Vaccinated" Immune Attacks

The clinical trial studies the human pathogen of SARS-CoV-2, with a specificity in the circulating Spike 2 protein in the human system. The clinical trial hypothesizes that SARS-CoV-2 human pathogen arises from immune attacks, underlying the severe physiological symptoms that can be lethal. It further hypothesizes that the vaccines do not deal with the Spike 2 protein that causes the immune attacks.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

1

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Chongqing
      • Chongqing, Chongqing, China, 402762
        • Residential Address

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • ADULT
  • OLDER_ADULT
  • CHILD

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • No mRNA vaccinated poisoning have been included currently, but scientific evidence suggest the methods of vaccination are irrelevant to the conditions. It is theorized that the more advanced the vaccine production technology, the deeper the poisoning.

Exclusion Criteria:

  • healthy individuals with no myocarditis or unvaccinated without infection by SARS-CoV series
  • persons with diabetes (Paxlovid and PrEP treatments can be applied according to availability)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: BASIC_SCIENCE
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Experiment Participant

COVID-19 recombined vaccinated, 3 dose, no intervention. Nifedipine, oral, 30 mg per day for 2 days, active comparative. Angiotensin-converting enzyme inhibitor, oral, gradually increase to 20 mg per day at night.

Beta blocker, oral, 23.75 - 95 mg per day in the morning. Proton-pump inhibitor, oral, 30 mg per day. Duloxetine hydrochloride, oral, placebo, 20 mg per day before sleep. Acetaminophen (sham comparator), oral, 250 mg four times per day for 8 days. Cefuroxime (sham comparator), oral, 100 mg twice per day for 6 days. Papaverine, oral, low-dosage in coughing pills for 4 days. Superoxide Dismutase (active comparator), oral, to be introduced. Bafilomycin A1 (active comparator), oral, 100 ug per kilogram per day, unlikely to be introduced for lack of funding.
Drug: Nifedipine 30 MG
Due to initial availability of drugs and the intensities of the patient's symptoms, Nifedipine was used for initial intervention in preventing acute myocarditis from happening.
Other Names:
  • Nifedipine Control-release Tablets
Diagnostic test: Kangzhu BPCB0A-3A
The diagnostic test has been used to confirm objective parameters to guide the intervention drug dosages and accessing the risks in sudden death and long term adverse effects.
Other Names:
  • Heart Monitor
Behavioral: Low Mobility
The behavioral intervention aimed at reducing the risks of sudden and strong blood flows in the patient's system.
Drug: Enalapril Maleate 10Mg Tab
The intervention aims to reduce the vein flows in Diastolic Blood Pressure, and the risks in blood clot formation and internal vein scratch bleeding.
Drug: Lansoprazole 30Mg Ec Cap
The intervention aims to server the allergy-inducing proteins to induce renal hemodialysis.
Drug: Metoprolol Succinate
Metoprolol Succinate is used to control the cardiac artery flow amounts and stabilize the patient's heart rate.
Dietary supplement: Coenzyme Q10
200 mg per day is used for supplement with the cardiac interventions.
Dietary supplement: d-alpha tocopherol acetate
The 268 mg twice per day dietary healthcare is the patient's usual daily use.
Dietary supplement: Omega-3
The 900 mg twice per day dietary healthcare is the patient's usual daily use.
Drug: Duloxetine Hydrochloride 20 MG Oral Capsule, Delayed Release
Duloxetine hydrochloride is used for the patient's neurodiverse conditions.
Other Names:
  • Neurodiverse
Drug: Superoxide Dismutase
Superoxide Dismutase is used to substitute the missing of antiviral drugs.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Heart Rate
Time Frame: 1 day
The heart rate is monitored daily, and the primary goal is to stabilize the patient's heart rate.
1 day
Electrocardiogram
Time Frame: 20 days
Electrocardiogram reflects the blood pressure management on the patient's health outcome and potential risks.
20 days
Platelet Distribution
Time Frame: 10 days
Platelet distribution is measured to determine the viral induced blood-borne pathogen in the physiological responses of the patient.
10 days
Mean Platelet Volume
Time Frame: 10 days
MPV is measured to determine the risks in blood clot and internal vein scratches in the patient.
10 days
Eosinophil Absolute Number
Time Frame: 10 days
Eosinophil Absolute Number is measured to determine the intensities of infection in the patient.
10 days
Basophil Absolute Number
Time Frame: 10 days
Basophil Absolute Number is measured on the counteraction of the patient's immune system integrities against the rapid acidification of the viral infection.
10 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cardiac Enzymes
Time Frame: 10 days
Cardiac enzymes are measured to locate and eliminate the symptoms' causes, identify potential health risks, and to determine if subsidiary treatments are needed.
10 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Yang I. Pachankis

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 2, 2023

Primary Completion (ACTUAL)

January 10, 2023

Study Completion (ACTUAL)

January 12, 2023

Study Registration Dates

First Submitted

January 12, 2023

First Submitted That Met QC Criteria

February 1, 2023

First Posted (ACTUAL)

February 3, 2023

Study Record Updates

Last Update Posted (ACTUAL)

February 3, 2023

Last Update Submitted That Met QC Criteria

February 1, 2023

Last Verified

February 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SARSCoVVaxPoison

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The emergent intervention started with the PI's research into the virology and post-vaccination adverse effects. The plan was improvised and adjusted accordingly. Statistical analysis was mainly physiological with relation to the virological inductions from the patient's symptomatic responses.

IPD Sharing Time Frame

The first 20 days of data have been uploaded on Zenodo, and significant results and monitoring data will be updated accordingly.

IPD Sharing Access Criteria

The data is openly available on Zenodo. The hospital facility and personnel involved for prescription drugs and tests are deidentified.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Study Data/Documents

  1. Clinical Study Report
    Information identifier: 10.5281/zenodo.7534361
    Information comments: The local hospital and medicare information are deidentified for their protection.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Renal Dialysis

Clinical Trials on Nifedipine 30 MG

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in New Zealand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe